{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38"],"submitter":["Gupta G"],"pubmed_abstract":["Donor-derived cell free DNA (dd-cfDNA) is an established biomarker for detection of rejection in single organ transplants; data is limited in multi-organ transplant (MOT) recipients. \"Use of dd-cfDNA in Multi-Organ Transplant Recipients\" (MOTR) was a multicenter, prospective, cross-sectional study that assessed dd-cfDNA fraction (%) and donor quantity score (DQS, cp/mL) in pancreas-kidney (PKT), heart-kidney (HKT), and liver-kidney (LKT) recipients. We explored dd-cfDNA baseline levels across the different organ combinations, and compared them to kidney-only (KT) and heart-only (HT) transplant recipients. Among 347 MOT recipients from 18 sites (PKT = 183, HKT = 57, LKT = 107), most (88.2%) had simultaneous transplants. Median dd-cfDNA levels in PKT and HKT recipients were not significantly"],"journal":["Transplant international : official journal of the European Society for Organ Transplantation"],"pagination":["15823"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12862255"],"repository":["biostudies-literature"],"pubmed_title":["Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)."],"pmcid":["PMC12862255"],"pubmed_authors":["Gong T","Daloul R","Bloom MS","Prewett A","Kaur N","Wojciechowski D","Bhorade S","Odorico JS","Spellicy CJ","Gauthier P","Rohan VS","Gude G","Dunn TB","Biagini DG","Costa N","Sener A","Ahmed E","Gupta G","Xie J","Al Haj Baddar N","Demko Z","Tabriziani H","Barnes D","Akkina SK"],"additional_accession":[]},"is_claimable":false,"name":"Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR).","description":"Donor-derived cell free DNA (dd-cfDNA) is an established biomarker for detection of rejection in single organ transplants; data is limited in multi-organ transplant (MOT) recipients. \"Use of dd-cfDNA in Multi-Organ Transplant Recipients\" (MOTR) was a multicenter, prospective, cross-sectional study that assessed dd-cfDNA fraction (%) and donor quantity score (DQS, cp/mL) in pancreas-kidney (PKT), heart-kidney (HKT), and liver-kidney (LKT) recipients. We explored dd-cfDNA baseline levels across the different organ combinations, and compared them to kidney-only (KT) and heart-only (HT) transplant recipients. Among 347 MOT recipients from 18 sites (PKT = 183, HKT = 57, LKT = 107), most (88.2%) had simultaneous transplants. Median dd-cfDNA levels in PKT and HKT recipients were not significantly","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-07-14T17:27:10.353Z","creation":"2026-06-21T03:12:46.643Z"},"accession":"S-EPMC12862255","cross_references":{"pubmed":["41635311"],"doi":["10.3389/ti.2025.15823"]}}